Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.

Oxford Nanopore Technologies, the company behind a new generation of sequencing-based molecular analysis technologies, and Cepheid, a leading molecular diagnostics company, today announced a strategic collaboration to develop and commercialize a seamless end-to-end workflow that combines Cepheid's GeneXpert system for pre-sequencing sample and library preparation with Oxford Nanopore's rapid, information-rich molecular analysis platform.

AdvaMed and nine other healthcare organizations have continued to pressure the White House to exempt medical devices and critical supplies from the Trump administration’s ongoing tariff saga.

Boditech Med, a global leader in point-of-care diagnostics, announced on the 7th that it held a successful completion ceremony for its new manufacturing facility located in Jhajjar, India. The new plant is a key part of the company’s strategy to strengthen its presence in the Indian, South Asian, and Middle Eastern markets through local production and enhanced cost competitiveness.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.

Tecan Group (SIX Swiss Exchange: TECN) today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits.

Dotmatics®, a leading provider of scientific software that provides end-to-end solutions to connect science, data, and decision making for life sciences R&D, today announced it has signed a definitive agreement to be acquired by Siemens AG for $5.1 billion.

Siemens Healthineers said Friday that it has received US Food and Drug Administration 510(k) marketing clearance for the use of its antithrombin activity assay as a companion diagnostic for Sanofi's Qfitlia (fitusiran), which was approved as a routine prophylaxis to prevent bleeding episodes in hemophilia patients.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States.

Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.